Research Papers
This database includes peer-reviewed publications authored or funded by TB Alliance. Use the tags on the right to filter by subject, or search for a particular author or term using the search bar.
Displaying 174 papers
The procurement landscape of pediatric tuberculosis treatment: a Global Drug Facility perspective
12/2015 - Scott C, Gardiner E, de Lucia A. The procurement landscape of pediatric tuberculosis treatment: a Global Drug Facility perspective. Int J Tuberc Lung Dis. 2015 Dec;19 Suppl 1:17-22. doi: 10.5588/ijtld.15.0478.
Pediatric tuberculosis drug market: an insider perspective on challenges and solutions
12/2015 - Usherenko I, Basu Roy U, Mazlish S, et. al. Pediatric tuberculosis drug market: an insider perspective on challenges and solutions. Int J Tuberc Lung Dis. 2015 Dec;19 Suppl 1:23-31. doi: 10.5588/ijtld.15.0479.
Paediatric formulations of second-line anti-tuberculosis medications: challenges and considerations
12/2015 - Taneja R, Garcia-Prats AJ, Furin J, Maheshwari HK. Paediatric formulations of second-line anti-tuberculosis medications: challenges and considerations. Int J Tuberc Lung Dis. 2015 Dec;19 Suppl 1:61-8. doi: 10.5588/ijtld.15.0435.
From availability to uptake: planning for the introduction of new, child-friendly anti-tuberculosis formulations
12/2015 - Malhotra S, Ursu I, Ghoneim R, et. al. From availability to uptake: planning for the introduction of new, child-friendly anti-tuberculosis formulations. Int J Tuberc Lung Dis. 2015 Dec;19 Suppl 1:32-8. doi: 10.5588/ijtld.15.0482.
Accelerating clinical drug development for children with tuberculosis
12/2015 - Murray S, McKenna L, Pelfrene E, Botgros R. Accelerating clinical drug development for children with tuberculosis. Int J Tuberc Lung Dis. 2015 Dec;19 Suppl 1:69-74. doi: 10.5588/ijtld.15.0616.
Towards early inclusion of children in tuberculosis drugs trials: a consensus statement
5/2015 - Nachman S, Ahmed A, Amanullah, et. al. Towards early inclusion of children in tuberculosis drugs trials: a consensus statement. Lancet Infect Dis. 2015 Jun;15(6):711-20. doi: 10.1016/S1473-3099(15)00007-9.
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant...
5/2015 - Dawson R, Diacon AH, Everitt D, et. al. Efficiency and safety of.... Lancet. 2015 May 2;385(9979):1738-47. doi: 10.1016/S0140-6736(14)62002-X.
Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models
4/2015 - Li SY, Irwin SM, Converse PJ, Mdluli KE, Lenaerts AJ, Nuermberger EL. Evaluation of moxifloxacin-containing regimens in pathologically distinct murine tuberculosis models. Antimicrob Agents Chemother. 2015 Jul;59(7):4026-30. doi: 10.1128/AAC.00105-15.
Bactericidal Activity of Pyrazinamide and Clofazimine Alone and in Combinations with Pretomanid and Bedaquiline
4/2015 - Diacon AH, Dawson R, von Groote-Bidlingmaier F, et. al. Bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med. 2015 Apr 15;191(8):943-53. doi: 10.1164/rccm.201410-1801OC.
Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis
2/2015 - Alffenaar JW, Gumbo T, Aarnoutse R. Shorter moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med. 2015 Feb 5;372(6):576. doi: 10.1056/NEJMc1414718#SA1.
The Tuberculosis Drug Discovery and Development Pipeline and Emerging Drug Targets
1/2015 - Mdluli K, Kaneko T, Upton A. The tuberculosis drug discovery and development pipeline and emerging drug targets.Cold Spring Harb Perspect Med. 2015 Jan 29;5(6). pii: a021154. doi: 10.1101/cshperspect.a021154.
Contribution of the Nitroimidazoles PA-824 and TBA-354 to the Activity of Novel Regimens in Murine Models of Tuberculosis
1/2015 - Tasneen R, Williams K, Amoabeng O, Minkowski A, Mdluli KE, Upton AM, Nuermberger EL. Contribution of the nitroimidazoles PA-824 and TBA-354 to the activity of novel regimens in murine models of tuberculosis. Antimicrob Agents Chemother. 2015 Jan;59(1):129
Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug
12/2014 - Svensson EM, Murray S, Karlsson MO, Dooley KE. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J Antimicrob Chemother. 2015 Apr;70(4):1106-14. doi: 10.1093/jac/dku504.
Evaluation of the Pharmacokinetic Interaction between Repeated Doses of Rifapentine or Rifampin and a Single Dose of Bedaquiline in Healthy Adult Subjects
12/2014 - Winter H, Egizi E, Erondu N, et. al. Evaluation of the pharmacokinetic interaction between repeated doses of rifapentine or rifampin and a single dose of bedaquiline in healthy adult subjects. Antimicrob Agents Chemother. 2015 Feb;59(2):1219-24. doi: 10.1
Strengthening neglected tropical disease research through enhancing research-site capacity: an evaluation of a novel web application to facilitate research collaborations
11/2014 - Furtado T, Franzen S, van Loggerenberg F, et. al. Strengthening neglected tropical disease research through enhancing research-site capacity: an evaluation of a novel web application to facilitate research collaborations. PLoS Negl Trop Dis. 2014 Nov 13;8
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis
10/2014 - New England Journal of Medicine
In Vitro and In Vivo Activities of the Nitroimidazole TBA-354 against Mycobacterium tuberculosis
10/2014 - Upton AM, Cho S, Yang TJ, et. al. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 2015 Jan;59(1):136-44. doi: 10.1128/AAC.03823-14.
Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 withconcomitant lopinavir-ritonavir, efavirenz, or rifampin
9/2014 - Dooley KE, Luetkemeyer AF, Park JG, et. al. Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin. Antimicrob Agents Chemother. 2014 Sep;58(9):5245-52.
Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibility
8/2014 - Streicher EM, Maharaj K, York T, et. al. Rapid sequencing of the Mycobacterium tuberculosis pncA gene for detection of pyrazinamide susceptibility.J Clin Microbiol. 2014 Nov;52(11):4056-7. doi: 10.1128/JCM.02438-14
Burden of childhood tuberculosis in 22 high-burden countries, a mathematical modelling study
7/2014 - Dodd PJ, Gardiner E, Coghlan R, Seddon JA. Burden of childhood tuberculosis in 22 high-burden countries: a mathematical modelling study. Lancet Glob Health. 2014 Aug;2(8):e453-9. doi: 10.1016/S2214-109X(14)70245-1.